OBJECTIVE: To determine the clinical presentation and clinical and radiological outcome of early @entity5144 ( @entity5144 ) at 1 and 2 yr. METHODS: @entity1 with @entity5144 were assessed at the St. Vincent's University Hospital Early Synovitis Clinic. Standardized clinical and laboratory assessment was performed at presentation and 1- and 2-yr follow-up. Radiographs of the hands and feet were evaluated in chronological order by two trained observers using the Sharp method modified to include the @entity571 ( @entity571 ) joints. RESULTS: A total of 129 (12.7%) of 1018 @entity1 were diagnosed with @entity5144 [mean age at onset of @entity625 was 40.4 yr (range 11-76); mean duration of disease was 9.9 months (range 0.3-48); 52 oligoarticular, 77 polyarticular]. Means and standard deviations of indices of disease activity at presentation were: 10-cm visual analogue scale = 4.8 +/- 2.7, HAQ score = 0.71 +/- 0.64, ACR functional class III/IV = 41 (35%), Ritchie Articular Index = 5.6 +/- 6, swollen joint count = 6.9 +/- 8, erythrocyte sedimentation rate = 24 +/- 26.4 mm/h, C-reactive protein = 27.6 +/- 58.5 mg/l. At presentation, 49 (38%) @entity1 had @entity1897 , 13 @entity1 (10%) had inflammatory spine pain and 50 (39%) @entity1 had @entity571 involvement. A total of 119 had @entity1569 at the time of presentation [plaque @entity1569 in 112 (94%), mean age of @entity1569 onset was 29.8 +/- 16.2 yr, @entity5806 present in 78 @entity1 (67%)]. At 1 yr of follow-up, 119 (92%) @entity1 were reassessed and 70 (59%) were taking a disease-modifying anti-rheumatic drug (DMARD). At 2 yr, 97 (75%) @entity1 were reassessed and 54 (56%) were taking a DMARD. Despite considerable improvement in @entity32 and function scores, only 31 (26%) @entity1 were in remission at 1 yr with 20 (21%) in remission at 2 yr. There was a low rate of DMARD-free remission [14 (12%) at 1 yr and 11 (11%) at 2 yr]. Radiographs of hands and feet were obtained for 117 (91%) @entity1 at presentation and 86 (67%) @entity1 at a median follow-up of 24 months (range 11-56); 47% of @entity1 had @entity2720 in hands or feet at follow-up with a mean Sharp erosion score of 3 (0) +/- 5.2 (range 0-25) and a mean Sharp narrowing score of 3.2 (0) +/- 7.5 (range 0-48). CONCLUSION: This study confirms that @entity5144 is a chronic, progressive disease in the majority of @entity1 . Despite clinical improvement with current DMARD treatment, @entity5144 results in radiological damage in up to 47% of @entity1 at a median interval of 2 yr.

A prospective, clinical and radiological study of early XXXX : an early synovitis clinic experience.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity571 :: ('MESH:D010003', 'Disease') :: ['DIP', 'distal interphalangeal'] @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis'] @entity5806 :: ('MESH:D009260', 'Disease') :: ['nail dystrophy'] @entity5144 :: ('MESH:D015535', 'Disease') :: ['PsA', 'psoriatic arthritis'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral enthesopathy'] @entity2720 :: ('MESH:D007592', 'Disease') :: ['joint erosions']
@entity5144 :: (MESH:D015535,Disease) :: ['psoriatic arthritis']
